Prevention of Osteoporosis in Men With Prostate Cancer

Completed · Phase 3

Conditions studied: Prostate Cancer, Osteoporosis, Hypogonadism

In brief

The purpose of this two year study is to examine the safety and effectiveness of alendronate (Fosamax) for the prevention of bone loss in men with prostate cancer who are on therapy to lower their testosterone levels. All men will receive appropriate calcium and vitamin D supplements and one to two years of alendronate therapy. Bone density tests will be done every six months.

Key facts

Study ID

NCT00048841

Run by

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

People needed

112

Starts

2002-05-01

Expected to finish

2005-12-01

Last updated by the study team

2010-03-02

Who can join

Age: 50 and older, up to 85. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Men age 50-85
• Stage D0 prostate cancer
• On androgen deprivation therapy

You may not qualify if…

• Renal failure
• Hyperthyroidism
• Cushing's syndrome
• Metabolic bone disease
• Use of glucocorticoids
• Use of certain anticonvulsants
• On osteoporosis therapies
• Nonprostate cancers

Where it is running

• Osteoporosis Prevention & Treatment Center — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.